Ultragenyx Pharmaceutical
RARE
154 hedge funds and large institutions have $2.16B invested in Ultragenyx Pharmaceutical in 2017 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 59 increasing their positions, 47 reducing their positions, and 18 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 47
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.98% less ownership
Funds ownership: 97.59% → 95.61% (-2%)
3% less funds holding
Funds holding: 158 → 154 (-4)
11% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 18
15% less capital invested
Capital invested by funds: $2.56B → $2.16B (-$394M)
39% less call options, than puts
Call options by funds: $7.34M | Put options by funds: $11.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$30.8M |
| 2 |
BlackRock
New York
|
+$15.7M |
| 3 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$13.7M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$11.6M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$9.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$64.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$16.5M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$15.4M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$12.7M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$8.86M |
RARE Hedge Fund Activity: Q3 2017 in Review
154 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q3 2017, worth a combined $2.16B — down 15% from $2.56B a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of RARE and 16 opened new positions — a net loss of 2 holders — while 47 trimmed existing stakes and 59 added.
The largest buyer was Capital International Investors, adding an estimated $30.8M. The largest seller was Capital Research Global Investors, cutting an estimated $64.8M.
- 154 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q3 2017, down from 158 in Q2 2017.
- Funds reported $2.16B of Ultragenyx Pharmaceutical stock for Q3 2017, down 15% quarter-over-quarter.
- 16 funds opened new Ultragenyx Pharmaceutical positions in Q3 2017 and 18 closed out, a net change of -2 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q3 2017 was Capital International Investors, an estimated $30.8M added.
- The largest Ultragenyx Pharmaceutical seller in Q3 2017 was Capital Research Global Investors, an estimated $64.8M sold.
Based on aggregated 13F filings for Q3 2017.